Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EZ-2053 for prophylaxis of acute pulmonary allograft rejection in adult lung transplant recipients
2005-001131-30Phase 3Completed
- Sponsor
- Fresenius
- Start
- Jun 2005
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory failure and Acute lung allograft rejection comparing EZ-2053 9 mg/kg with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jun 2005; status: completed.
02
Drugs
grafalon
03
Conditions
respiratory failureAcute lung allograft rejection
Beyond the preview
Go deeper on 2005-001131-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001131-30.